Stock Scorecard

Stock Summary for Genmab (GMAB) - $26.14 as of 3/16/2026 1:58:13 PM EST

Total Score

14 out of 30

Safety Score

63 out of 100

Currently on the following lists
None
Tim's Recommendation
Possible Buy

Growth List Algorithm Criteria for GMAB

Positive Quarterly and Annual earnings growth
P/E ratio less than Industry P/E Ratio
P/E ratio less than Sector P/E Ratio
P/E ratio that is half the Annual earnings growth rate (or less)
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Positive net income past year and 12 trailing months
Free cash flow ratio greater than 0 and less than 10

Small Cap List Algorithm Criteria for GMAB

Revenue growing by at least 20% average per year over the last 5 years
Market Capitalization under 2 billion
Price to Sales (P/S) ratio 12 trailing months less than Industry P/S ratio twelve trailing months
Price to Sales (P/S) ratio 12 trailing months less than Sector P/S ratio twelve trailing months
Net Income past year > Net Income prior year OR Net Income 12 trailing months > Net Income prior year OR Net Income 12 trailing months > Net Income past year

Dividend List Algorithm Criteria for GMAB

Declared an ex-dividend date
Forward annual dividend rate greater than 2
Positive net cash position the past year and most recent quarter
Equity to debt ratio greater than 0.75 for past year and most recent quarter
Current ratio most recent quarter greater than 2
Cash Flow per Share greater than Trailing Dividend Rate

Bonus Criteria for GMAB

P/E ratio less than five-year Average P/E ratio
Last Price to 52 Week Low Ratio Less Than 1
Total Cash Per Share > Last Day Price
P/S Ratio < 1
P/B Ratio < 1

Safety Rating Criteria for GMAB (63 out of 100)

Stock Price Rating (Max of 10) 7
Historical Stock Price Rating (Max of 10) 8
Stock Price Trend (Max of 10) 2
Book Value (Max of 10) 9
Book Value to Price (Max of 10) 10
Analyst Buy Ratings (Max of 5) 5
Analyst Strong Buy Ratings (Max of 5) 0
Dividend Yield Percentage (Max of 10) 0
Operating Margin (Max of 10) 5
Trading Volume (Max of 10) 9
Price to Earnings (Max of 10) 8
Geopolitical Risk Adjustment (Always 0 for USA or a Negative Number for Non-USA) 0

Financial Details for GMAB

Company Overview
Ticker GMAB
Company Name Genmab
Country USA
Description Genmab A / S develops antibody therapies for the treatment of cancer and other diseases mainly in Denmark. The company is headquartered in Copenhagen, Denmark.
Sector Name HEALTHCARE
Industry Name BIOTECHNOLOGY
Most Recent Quarter 12/31/2025
Next Earnings Date 5/7/2026

Stock Price History
Last Day Price 26.14
Price 4 Years Ago 42.38
Last Day Price Updated 3/16/2026 1:58:13 PM EST
Last Day Volume 1,032,906
Average Daily Volume 1,637,984
52-Week High 35.43
52-Week Low 17.23
Last Price to 52 Week Low 51.71%

Valuation Measures
Trailing PE 16.97
Industry PE 24.56
Sector PE 40.66
5-Year Average PE 30.85
Free Cash Flow Ratio 1.48
Industry Free Cash Flow Ratio 10.30
Sector Free Cash Flow Ratio 22.88
Current Ratio Most Recent Quarter 2.02
Total Cash Per Share 17.71
Book Value Per Share Most Recent Quarter 94.89
Price to Book Ratio 2.75
Industry Price to Book Ratio 54.44
Sector Price to Book Ratio 36.53
Price to Sales Ratio Twelve Trailing Months 4.32
Industry Price to Sales Ratio Twelve Trailing Months 32.06
Sector Price to Sales Ratio Twelve Trailing Months 12.34
Analyst Buy Ratings 6
Analyst Strong Buy Ratings 0

Share Statistics
Total Shares Outstanding 614,869,000
Market Capitalization 16,072,675,660
Institutional Ownership 12.12%

Dividends
Ex-Dividend Date N/A
Previous Dividend Amount 0.0000
Current Dividend Amount 0.0000
Total Years Dividend Increasing N/A
Trailing Annual Dividend Rate 0.00
Trailing Annual Dividend Yield 0.00%
Forward Annual Dividend Rate 0.00
Forward Annual Dividend Yield 0.00%
5-Year Dividend Payments Count 0
3-Year Average Dividend Yield 0.00%
5-Year Average Dividend Yield 0.00%
1-Year Dividend Growth Rate Percentage 0.00%
3-Year Dividend Growth Rate Percentage 0.00%
5-Year Dividend Growth Rate Percentage 0.00%
All-Time Dividend Growth Rate Percentage 0.00%
Dividend Payout Ratio N/A

Income Statement
Quarterly Earnings Growth YOY -94.40%
Annual Earnings Growth -21.69%
Reported EPS 12 Trailing Months 1.54
Reported EPS Past Year 1.71
Reported EPS Prior Year 1.74
Net Income Twelve Trailing Months 2,922,221,193
Net Income Past Year 6,142,507,928
Net Income Prior Year 7,844,000,000
Quarterly Revenue Growth YOY 3.00%
5-Year Revenue Growth 18.60%
Operating Margin Twelve Trailing Months 23.00%

Balance Sheet
Total Cash Most Recent Quarter 10,905,590,846
Total Cash Past Year 10,905,590,846
Total Cash Prior Year 9,858,000,000
Net Cash Position Most Recent Quarter 5,904,590,846
Net Cash Position Past Year 5,904,590,846
Long Term Debt Past Year 5,001,000,000
Long Term Debt Prior Year 0
Total Debt Most Recent Quarter 5,001,000,000
Equity to Debt Ratio Past Year 0.88
Equity to Debt Ratio Most Recent Quarter 0.88
Total Stockholder Equity Past Year 37,180,752,000
Total Stockholder Equity Prior Year 36,697,000,000
Total Stockholder Equity Most Recent Quarter 37,180,752,000

Free Cash Flow
Free Cash Flow Twelve Trailing Months 4,441,113,300
Free Cash Flow Per Share Twelve Trailing Months 7.22
Free Cash Flow Past Year 7,328,911,322
Free Cash Flow Prior Year 7,584,000,000

Options
Put/Call Ratio 0.19
Has Options Options Chain
Liquidity Rating

Technical Analysis
Yahoo Finance Chart Yahoo Finance Chart
MACD 0.00
MACD Signal 0.00
20-Day Bollinger Lower Band 0.00
20-Day Bollinger Middle Band 0.00
20-Day Bollinger Upper Band 0.00
Beta 0.75
RSI 0.00
50-Day SMA 0.00
150-Day SMA 0.00
200-Day SMA 0.00

System
Modified 3/16/2026 11:45:17 PM EST